NCT06435702 - Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

December 31, 2029

Conditions

Prostate Cancer

Interventions

DRUG

Darolutamide in addition to androgen deprivation therapy

Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration

DRUG

androgen deprivation therapy only

The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing